Valbenazine: Drug review
| Autor: | Mahanjit Konwar, Nithya J Gogtay, Urmila M Thatte |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: | |
| Zdroj: | Annals of Indian Psychiatry, Vol 1, Iss 2, Pp 84-87 (2017) |
| Druh dokumentu: | article |
| ISSN: | 2588-8358 2588-8366 |
| DOI: | 10.4103/aip.aip_41_17 |
| Popis: | Valbenazine is the first drug approved by the US Food and Drug Administration for the treatment of adults with tardive dyskinesia (TD) on April 11, 2017. It acts as a reversible inhibitor of vesicular monoamine transporter 2. It is available orally with a starting dose of 40 mg once daily which can be increased after 1 week to the recommended dose of 80 mg. Clinical trials showed positive outcomes in Abnormal Involuntary Movement Scale and Clinical Global Impression - Global Improvement of TD score with respect to placebo. Valbenazine has an acceptable safety and tolerability profile, the most common side effect observed is somnolence. However, long-term study is lacking, and more data are required to establish its full benefits and concomitant risks which can be missed in the recent trials. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|